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Abstract
Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal
growth factor receptor (EGFR) and human EGFR2 (HER2) is observed frequent in pancreatic adenocarcinomas.
Because of co-activation of these two signaling pathways, we assessed the efficacy of inhibition of EGFR/HER2
receptors and the downstream KRAS effector, mitogen-activated protein kinase/extracellular-signal regulated ki-
nase (ERK) kinase 1 and 2 (MEK1/2), on pancreatic cancer proliferation in vitro and in a murine orthotopic xenograft
model. Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trame-
tinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition
elicited by trametinib in three of eight cell lines. Importantly, in the orthotopic xenograft model, treatment with
lapatinib and trametinib resulted in significantly enhanced inhibition of tumor growth relative to trametinib treatment
alone in four of five patient-derived tumors tested and was, in all cases, significantly more effective in reducing the
size of established tumors than treatment with lapatinib or trametinib alone. Acute treatment of established tumors
with trametinib resulted in an increase in AKT2 phosphorylation that was blunted in mice treated with both trame-
tinib and lapatinib. These data indicate that inhibition of the EGFR family receptor signaling may contribute to the
effectiveness of MEK1/2 inhibition of tumor growth possibly through the inhibition of feedback activation of receptor
tyrosine kinases in response to inhibition of the RAS-RAF-MEK-ERK pathway. These studies provide a rationale for
assessing the co-inhibition of these pathways in the treatment of pancreatic cancer patients.
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Introduction
Pancreatic cancer is associated with the shortest survival of any solid
malignancy, and while survival has improved for most other cancers
over the last several decades, the 5-year survival for pancreatic cancer
remains below 5% [1]. The refractory nature of pancreatic cancers to
cytotoxic and targeted therapies is likely due in part to the complex
molecular signaling in pancreatic cancer [2]. The progression of pan-
creatic cancer from dysplasia to invasive carcinoma is accompanied
by mutations in multiple genes that in turn alter core signaling
and regulatory pathways [3]. Invasive cancers exhibit a high frequency
of activating mutations in the KRAS oncogene, inactivation of the
tumor suppressor genes p16/CDKN2A and TP53, and the inactiva-
tion of SMAD family member 4 gene (SMAD4) [4–6]. Oncogenic
KRAS mutations have been reported to occur in as many as 75% to
93% of pancreatic cancers [7,8]. These observations coupled with
studies showing that, in genetically engineered mice, mutation of
KRAS and the deletion of TP53 or p16/CDKN2A yields pancreatic
cancers with properties very similar to human pancreatic cancers [9]
identify mutation of KRAS as an important driver of pancreatic
cancer progression.
In addition to KRAS mutation, activation of cell surface receptor
tyrosine kinases (RTKs) also plays an important role in pancreatic
cancer progression. Indeed, one or more of the members of the epi-
dermal growth factor (EGF) family of receptors is expressed in a large
proportion of pancreatic cancers [10,11]. The EGF receptor (EGFR)
inhibitor erlotinib is approved for use in metastatic pancreatic cancer,
although its overall efficacy in clinical trials of unselected patients has
been minimal [12]. A recent report shows that overexpression of
HER2 receptors is an independent factor for a worse patient outcome
[13]. In preclinical studies, the combination of cetuximab (anti-EGFR
monoclonal antibody) and trastuzumab (anti-HER2 monoclonal anti-
body) exhibited a synergistic therapeutic effect on the growth of
human pancreatic cancer xenografts [14]. How the activation of signal-
ing pathways downstream of EGFR influence the constitutive signal-
ing manifest by mutated KRAS is poorly understood but appears
to play an important role in pancreatic cancer.
The mitogen-activated protein kinase (MAPK) kinase (MEK)–
ERK pathway is a major therapeutic target in cancers with gain-of-
function mutations in KRAS and BRAF. A number of small molecule
inhibitors of both RAF and MEK1/2 are in clinical development and
in early studies have proven efficacious in inhibiting the growth of
RAS/RAF-driven tumors [15,16]. To provide insights into how hu-
man pancreatic cancer proliferation is impacted by therapeutic target-
ing of the RAS pathway, we have used a preclinical transplant model
in which surgically resected human pancreatic cancers are orthoto-
pically xenografted into immunocompromised mice. Growth and
propagation of the patient-derived tumors allows the molecular, cel-
lular, and genetic interrogation of individual tumors and assessment
of their susceptibility to targeted therapy. An initial analysis of 15
patient-derived tumors shows the high frequency of expression of
tyrosine-phosphorylated EGFR and less frequent expression of
tyrosine-phosphorylated HER2, along with a high frequency of KRAS
mutations. Because of the frequency of co-expression of oncogenic
KRAS mutations and EGFR family receptors, coupled with prior evi-
dence for the importance of both EGFR and KRAS signaling pathways,
we sought to determine whether inhibition of the EGFR/HER2 recep-
tors would augment the inhibition of pancreatic cancer proliferation
caused by blocking signaling by the downstream KRAS effector,
MEK1/2. Using both in vitro cell culture and mouse orthotopic xeno-
graft models, we assessed the combined activities of lapatinib, an inhib-
itor of human EGFR2 (HER2) and EGFR tyrosine kinase activity
[17–19], and trametinib (GSK1120212), a potent and selective allo-
steric inhibitor of mitogen-activated protein kinase/extracellular-signal
regulated kinase (ERK) kinase 1 and 2 (MEK1/2) [20–22] with prom-
ising antitumor activity in phase I/II clinical trials [23].
We observed that while the inhibition of MEK1/2 blocked pan-
creatic cancer cell proliferation in all cell lines tested, we noted that
the combined inhibition of EGFR/HER2 and MEK1/2 signaling
augmented inhibition of cell proliferation in some but not all cell
lines. Importantly, when assessed in the orthotopic xenograft model,
treatment with lapatinib and trametinib resulted in significantly
enhanced inhibition of tumor growth relative to trametinib treat-
ment alone in four of five patient-derived tumors. In addition, treat-
ment of established tumors with lapatinib and trametinib was again
significantly more effective in reducing the size of established tumors
than treatment with lapatinib or trametinib alone. Acute treatment
of established tumors with trametinib resulted in an increase in
AKT2 phosphorylation that was blunted in mice treated with both
trametinib and lapatinib. These data provide evidence that inhibition
of the EGFR family receptor signaling may enhance the effectiveness
of MEK1/2 inhibition of tumor growth in an orthotopic setting.
Recent studies of breast cancers demonstrated that inhibition of
MEK1/2 signaling leads to the feedback up-regulation of RTK
signaling and the reactivation of MEK-ERK [24,25]. We suggest that
the action of lapatinib in combination with trametinib may be to
blunt signals from treatment-dependent activation of EGF family
receptors, thus augmenting the inhibition of pancreatic cancer cell
proliferation. Our results provide a rationale for further experiments
to assess this therapeutic combination in the treatment of pancreatic
cancer patients.
Materials and Methods
Isolation and Propagation of Patient-Derived Tumors in
Immunocompromised Mice
The harvest, pathologic examination, and propagation of human
pancreatic cancer specimens have been described previously [26].
Human tumor tissue was resected and, following pathologic assess-
ment, sutured onto the pancreases of 6- to 8-week-old male NOD.
SCID/NCr mice. Tumors (typically arising after 3–6 months) were
harvested (termed F1) and reimplanted into 6- to 8-week-old male
athymic nude mice for serial propagation (termed F2, F3, etc). Patho-
logic review was conducted for all F0 and F1 tumors as well as select late
passage tumors, and tumor grade and stromal content were scored.
Cell Lines, Antibodies, and Inhibitors
Four pancreatic cancer cell lines, MPanc96, L3.6pl, PANC-1, and
BxPC-3, were maintained as previously described [26]. The human
pancreatic cancer cell line L3.6pl was kindly provided by I. J. Fidler
(The University of Texas M.D. Anderson Cancer Center, Houston,
TX; August 2005) [27]. MPanc-96, PANC-1, and BxPC-3 were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD; August 2005) and maintained in Dulbecco’s modi-
fied Eagle’s medium (MPanc-96, PANC-1) or RPMI (BxPC3) sup-
plemented with 10% FBS and antibiotics. Fresh patient-derived cell
lines (608, 738, 366, and 450) were obtained under Institutional
Review Board (IRB) protocol as previously described [26]. All cell lines
were expanded, aliquoted, and frozen upon initial receipt; cells were
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thawed, propagated, and used for experiments every 6 months.
MPanc-96, PANC-1, and BxPC-3 were authenticated before purchase
by the ATCC with cytochrome c oxidase subunit 1 analysis, DNA
profiling, cytogenetic analysis, flow cytometry, and immunocyto-
chemistry. L3.6pl cells and the fresh patient-derived cells (608, 738,
366, and 450) were authenticated in 2010 and 2011 by the University
of Virginia Biomolecular Research Facility with DNA profiling, cyto-
genetic analysis, flow cytometry, and immunocytochemistry. Anti-
bodies used for Western blot analysis included β-actin, phospho-ERK
and ERK (Sigma, St Louis, MO), EGFR (R&D Systems, Minneapolis,
MN; Cell Signaling Technology, Danvers, MA), HER2/Neu (Santa
Cruz Biotechnology, Santa Cruz, CA), AKT, phospho-AKT, SRC,
phospho-SRC, and RAN (Cell Signaling Technology). Erlotinib was
kindly provided by OSI Pharmaceuticals (Melville, NY) and lapatinib
and trametinib (GSK1120212) by GlaxoSmithKline. Immunohisto-
chemistry was performed as described previously [26].
Analysis of Genetic Mutations
DNA was extracted using the PureLink Genomic DNA Kit
(Invitrogen, Carlsbad, CA) or from frozen tissue samples preserved
in Allprotect tissue reagent using the AllPrep Kit (Qiagen, Valencia,
CA). Polymerase chain reaction (PCR) amplification was carried out
using BIO-X-ACT short mix (Bioline, Taunton, MA) in a Techgene
(Burlington, NJ) or Mastercycler gradient (Eppendorf, Hauppauge,
NY) machine using PCR primers and programs based on published
protocols. Purification of the PCR product was accomplished using
QIAquick Spin Kit (Qiagen), and sequence analysis was performed
by the University of Virginia Biomolecular Research Facility and
analyzed using the software Vector NTI (Invitrogen).
RTK and Protein Kinase Array Analysis, Western Blot
Analysis, and Immunohistochemistry
The activation status of 42 RTKs and 26 protein kinases including
nineMAPKs was assessed using the Proteome Profiler Human Phospho-
RTKArray Kit andHuman Phospho-MAPKArray Kit (R&DSystems).
Briefly, cells or mechanically disrupted tumor samples were lysed directly
in NP-40 lysis buffer. Lysates were cleared by centrifugation at 13,000g
for 10 minutes and quantified by bicinchoninic acid assay (BCA). Each
array was exposed to 250 μg of total protein from cell or tumor lysates.
Arrays were developed using Pierce ECL Substrate (Thermo Fisher
Scientific, Inc, Waltham, MA) per manufacturer’s instructions and
analyzed using a Bio-Rad GS-800 calibrated densitometer (Bio-Rad,
Hercules, CA) and ImageQuant TL 2005 (GE Healthcare, Piscataway,
NJ) software. For Western blot analysis, 20 to 25 μg of total protein
was subjected to polyacrylamide gel electrophoresis–sodium dodecyl
sulfate. Gels were transferred to nitrocellulose, probed with designated
antibodies, and developed with ECL substrate.
In Vitro Proliferation Assays
Cells (1.5 × 103 to 3 × 103) were plated onto a 96-well plate in
serum containing media and allowed to attach overnight. Following
1 day of growth, cell number was determined and drug treatment
was initiated as indicated and replenished 48 hours later. Cells were
harvested 5 days later, and the CyQUANT cell proliferation assay
(Invitrogen) was used to determine relative cell number in the wells,
using fluorescence measured by a plate reader (Biotek, Winooski, VT).
In Vivo Studies
Tumor pieces (approximately 50 mg) were orthotopically implanted
onto the pancreases of 6- to 8-week-old male athymic nude mice.
Tumors were allowed to grow for 1 to 2 weeks, at which point drug
treatment commenced. Mice received lapatinib (65 mg/kg, orally,
twice daily), trametinib (0.3 mg/kg, orally, once daily), or a combi-
nation of lapatinib and trametinib. Mice underwent necropsy as indi-
cated, and tumors were weighed, measured by calipers, and examined
for presence of metastatic disease.
For tumor regression studies, tumors were implanted and allowed
to grow to a volume of 250 to 500 mm3 as assessed by volumetric
magnetic resonance imaging (MRI). Mice were then treated as above.
As indicated, the dose of trametinib was increased to 1.0 mg/kg daily.
MRI was used to assess tumor volume at 7- to 10-day intervals. After
3 to 4 weeks of treatment, drug was removed and tumors were
allowed to grow for a period of 1 to 3 weeks.
To evaluate acute treatment response, tumors were implanted and
allowed to grow for 3 to 4 weeks until palpable. Mice were then treated
with vehicle control, lapatinib (65 mg/kg, orally, twice daily), trame-
tinib (3 mg/kg, orally, daily), or combination therapy for 24 hours
before sacrifice and tumor harvest.
MRI Assessment of Tumor Growth
For MRI, mice were anesthetized and 0.5-mm axial imaging slices
were generated, encompassing the entire tumor. Tumor area was
measured for each individual image slice, and tumor volume was cal-
culated using the following equation: VolumeTUMOR = (AreaIMAGE1 +
AreaIMAGE2 + AreaIMAGE3…) as described previously [26].
Statistical Analyses
For statistical analyses, all group comparisons were unpaired.
Categorical variables were compared using either Fischer exact or
Pearson chi-square tests as appropriate. Analysis of variance was used
to compare continuous variables. All categorical variables have been
expressed as a percentage of the group of origin, and continuous vari-
ables were expressed as means ± SD. All P values reported are two-
tailed, and statistical significance was indicated by P values of <.05.
GraphPad Prism (Version 5.0b) software (La Jolla, CA) was used for
all statistical analyses.
Results
Pathologic, Genetic, and Molecular Characterization
of Tumors
Using an orthotopic transplantation model, we propagated a diverse
population of surgically resected human pancreatic cancers of various
stages, grades, and stromal content in the pancreases of NOD.SCID/
NCr mice [28]. Pathologic assessment of 15 patient tumors revealed
67% high-grade (grade III) tumors with 60% occurring as primary
adenocarcinomas of the pancreas and 40% being derived from meta-
static lesions. KRASmutations were observed in 67% (codon 12), 73%
had mutations in TP53, 71% had mutations in SMAD4, and 43% had
mutation or methylation of p16 (data not shown). No mutations in
BRAF or BRCA2 were observed and only one tumor possessed mutated
PI3K (data not shown). Table 1 summarizes the pathologic and genetic
characteristics of five representative patient-derived tumors/cell lines as
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well as four well-characterized pancreatic cancer cell lines (MPanc96,
L3.6pl, BxPC-3, and PANC-1) used in the studies described herein.
The diversity of expression of RTKs in pancreatic cancer is poorly
understood. To better understand the spectrum of RTKs that may
be involved in driving pancreatic cancer progression, the 15 patient-
derived tumors and four cell lines were interrogated using phospho-
RTK arrays formatted to detect activated (tyrosine-phosphorylated)
receptors. Figure 1A compares the relative tyrosine phosphorylation
of individual RTKs within the panel of tumors and cell lines. Robust
expression of phospho-EGFR was observed in all cell lines and
patient-derived tumors. In contrast, expression of phospho-HER2
was observed in only a subset (47%) of patient-derived tumors. In
addition to phospho-EGFR and phospho-HER2, we observed ex-
pression of phosphorylated fibroblast growth factor receptor 1 and 3
(FGF-R1/3) in a high proportion of patient-derived tumors, whereas
expression of phosphorylated macrophage-stimulating protein (MSP)
and vascular endothelial growth factor receptors were expressed at lower
levels and in a small subset of patient-derived tumors.
A parallel analysis of total EGF and HER2 receptor expression was
carried out in four pancreatic cell lines and cells from four patient-
derived tumors using Western blot. Analysis of patient-derived tumors
confirmed the expression of EGFR and HER2 in each of the tumors,
although the level of expression varied substantially among the lines.
HER2 expression was substantially lower than that observed in the
breast cancer cell line, SK-BR-3, a cell line having amplified HER2
(Figure 1B). These data support previous observations of EGFR and
HER2 expression in human pancreatic cancers and suggest that the
activation (as measured by tyrosine phosphorylation) of these receptors
can vary from tumor to tumor presumably reflecting the exposure to
ligand within the microenvironment of the tumor.
Results of In Vitro Treatment with Lapatinib and
MEK Inhibitor
On the basis of the frequent expression of activated EGF and HER2
receptors and the mutation of KRAS in a majority of the tumors, we
examined the contributions of these signaling pathways on the growth
of eight pancreatic cancer cell lines, four of which were derived from
patient tumors within our tumor bank. Treatment of individual cell
lines with 1 μM lapatinib revealed modest but statistically significant
Table 1. Tumors and Cell Lines.
Tumor/Cell Line Primary or Metastatic Grade Stromal Content Genetic
Alterations
KRAS p53
608 tumor Metastatic High Low mut mut
738 tumor Primary High High wt mut
232 tumor Primary High High mut mut
366 tumor Metastatic High Low mut mut
450 tumor Primary Low High mut mut
MPanc96 Primary Low High mut mut
L3.6pl Metastatic High High mut wt
BxPC-3 Primary High Unknown wt mut
PANC-1 Primary High Low mut mut
mut, mutation; wt, wild type.
Figure 1. (A) Relative activation of selected RTKs for 15 patient-derived pancreatic cancer lysates and four established pancreatic cancer
cell lines (black, more than three times the threshold; dark gray, two to three times the threshold; light gray, one to two times the
threshold). (B) Western blots for EGFR and HER2 in four patient-derived pancreatic cancers, established pancreatic cancer cell lines,
and SK-BR-3, a breast cancer cell line (asterisk represents a 1-s exposure).
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Figure 2. Proliferation assays for four established pancreatic cancer cell lines (A–D) and four patient-derived pancreatic cancer cell lines
(E–H) after treatment with DMSO (control), lapatinib (1.0 μM), trametinib (0.3 μM), or combination of lapatinib and trametinib. P values
are given as follows: *P < .05, **P < .01, ***P < .001.
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growth inhibition in four of the eight cell lines tested in a 5-day pro-
liferation assay (Figure 2). Treatment of the HER2-overexpressing
breast cancer cell line SK-BR-3 with similar concentrations of lapatinib
yielded virtually complete inhibition of growth (data not shown) con-
sistent with the importance of this signaling pathways in these cells.
We next assessed the contribution of the MEK-ERK pathway in
pancreatic cancer growth treating the individual cell lines with 0.3 μM
trametinib, an allosteric inhibitor of MEK1/2 activity (Figure 2). At
this concentration, inhibition of cell proliferation was observed for all
cell lines, but the extent of inhibition varied from complete [i.e.,
below day 1 levels (indicated by the dotted lines) in BxPC-3, 366,
608, and 450 tumor cells] to 46% (PANC-1; Figure 2). Combined
treatment of the panel of cell lines with both lapatinib (at 1.0 μM)
and trametinib (at 0.3 μM) enhanced the inhibition of cell growth
in three of the cell lines (L3.6pl, BxPC-3, and 366 cells; Figure 2).
To further examine the combinatorial effects of the two inhibitors, we
treated cells with 1.0 μM lapatinib and increasing concentrations of
trametinib. As shown in Figure W1, BxPC-3 and 366 cells exhibited
a left shift in the half-maximal inhibitory concentration (IC50) when
lapatinib was added to trametinib. However, most tumor-derived cell
lines exhibited little alteration in the IC50 for proliferation when treated
with both lapatinib and trametinib (data not shown). Treatment with
trametinib or the combination of lapatinib and trametinib was often
cytotoxic, with fewer cells being observed at the end of the 5-day growth
assay compared to the number of cells at day 1, the time of first addition
of drug (Figures 2 andW1). Increased caspase-3 expression was noted in
most cell lines exhibiting extensive cell death after combined treatment,
consistent with an increased extent of apoptosis (data not shown).
To confirm targeting and inhibition of EGFR and HER2 receptor
activity in the tumor cell lines, we treated cells with 1.0 μM lapatinib
for 6 hours and interrogated cell extracts using phospho-RTK arrays.
As shown in Figure 3, A to C , treatment of patient-derived cell lines
led to a 72% to 92% inhibition of EGFR activity and a 94% to 98%
inhibition of HER2 activity. Treatment with lapatinib had no effect
on the activation status of FGF (Figure 3, A–C ) or mesenchymal
epithelial transition factor (c-MET) receptors (data not shown).
To confirm the inhibition of the MEK-ERK pathway following
treatment with lapatinib, trametinib, or the combination, we treated
cells with drug for 6 hours and probed cell extracts for phospho-ERK
using Western blot analysis (Figure 3, D and E ). Treatment with
lapatinib showed variable inhibition of ERK phosphorylation, being
most evident in MPanc96, BxPC-3, and 738 cells, the latter two lines
wild type for KRAS. Treatment with trametinib or the combination of
lapatinib and trametinib completely inhibited ERK phosphorylation.
Figure 3. (A–C) Treatment of three patient-derived pancreatic cancer cell lines with DMSO (control) and lapatinib (1.0 μM), showing
relative phosphorylation of EGF and FGF family RTKs (ND, no detection of pRTK). (D and E) Western blot analysis for ERK and pERK
in three patient-derived pancreatic cancer cell lines and four established cell lines after treatment with DMSO, lapatinib (1.0 μM),
trametinib (0.3 μM), and combination.
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Figure 4. (A–E) In vivo response of five different human-derived pancreatic cancers after treatment with vehicle control, lapatinib (L;
65 mg/kg, twice daily), trametinib (0.3 mg/kg, daily), or combination (L + T). (F) Summary of liver metastasis for the same five tumors.
(G) Observed liver metastases in mice bearing individual patient-derived tumors. P values are given as follows: *P < .05, **P < .01,
***P < .001.
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Figure 5. Response of established tumors (A–C) following treatment with lapatinib (65 mg/kg, twice daily; circles), trametinib (0.3 mg/kg,
daily; squares), or combination (triangles). The tumors were allowed to grow to 250 to 500 mm3 before the onset of treatment. Arrows
denote a dose escalation of trametinib to 1.0 mg/kg daily. The right panels show MRIs at the specified time points for representative
mice treated with the combination of lapatinib and trametinib with tumors outlined. P values are given as follows and indicate significance
of combination treatment versus trametinib alone: *P < .05, **P < .01, ***P < .001.
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These data are consistent with inhibition of the MEK-ERK signaling
pathway being the major determinant of the observed inhibition of
cell proliferation in vitro. To assess the extent to which EGF-dependent
pathways contribute to activation of ERK phosphorylation, we
examined the response of the patient-derived 366 tumor cells to
EGF stimulation in culture. As shown in Figure W2, addition of
EGF to serum-starved 366 cells stimulated ERK phosphorylation
approximately two-fold, showing that in spite of the mutation of KRAS,
these tumor cells continue to respond to growth factor–mediated
signals. Treatment with lapatinib blocked EGFR phosphorylation
(top lanes) and dampened ERK phosphorylation. Treatment with
trametinib or the combination of trametinib and lapatinib at concen-
trations that completely inhibited cell growth fully inhibited ERK
phosphorylation as expected.
Results of In Vivo Treatment with Lapatinib and
MEK Inhibitor
We next tested the efficacy of drug treatment using orthotopic
implantation of patient-derived tumors into the pancreases of immuno-
compromised mice. Five tumors (608, 738, 366, 232, and 450) were
implanted, allowed to grow for 1 to 2 weeks, and treated with either
lapatinib alone, trametinib alone, or with a combination of lapatinib
and trametinib (Figure 4). Tumors were allowed to grow for 4 to
5 weeks in the presence or absence of inhibitors, and tumor mass
and presence of liver metastasis was assessed at necropsy. Only in the
patient-derived 450 tumor was there a statistically significant inhibi-
tion of tumor growth upon treatment with lapatinib (65 mg/kg,
twice daily; Figure 4D). Treatment with trametinib (0.3 mg/kg, daily)
alone resulted in significantly better inhibition of tumor growth, with
statistically significant inhibition observed in all treatment groups.
Treatment with combination of lapatinib and trametinib resulted in
significantly greater inhibition of tumor growth than that achieved with
lapatinib in all tumors and trametinib (Figure 4, A–E ) in four of the
five tumors tested. As shown in Figure 4, F and G , treatment with a
combination of lapatinib and trametinib resulted in an 84% decrease in
liver metastasis compared to control-treated mice (P < .01) and fewer
metastases than mice treated with either lapatinib or trametinib alone.
Treatment of Advanced Tumors In Vivo
To assess whether the individual treatment regimens would result
in tumor stasis or regression, three different patient-derived tumors
were implanted in the pancreases of immunocompromised mice and
allowed to grow for 3 to 4 weeks achieving a tumor volume of 250 to
500 mm3 as determined by MRI. Cohorts of 5 to 10 animals were
Figure 6. In vivo effects of inhibitor therapy on MEK1/2 signaling. Mice orthotopically implanted with patient-derived tumors 366
(A), 608 (B), and 738 (C) were treated for 24 hours with vehicle control, lapatinib (65 mg/kg, twice daily), trametinib (3 mg/kg, daily),
or combination of lapatinib (65 mg/kg) and trametinib (3 mg/kg, daily) and then sacrificed. Whole tumor lysates from these animals were
analyzed by Western blot analysis with the indicated antibodies. Each lane represents the tumor lysate of an individual experimental
mouse exposed to the indicated treatment condition.
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treated with lapatinib (65 mg/kg, twice daily) alone, trametinib
(0.3 mg/kg, daily) alone, or a combination of lapatinib and trame-
tinib, and tumor volume was monitored by MRI every 7 to 10 days.
The 738 tumor, a KRAS wild-type tumor, showed no growth inhibi-
tion following treatment with lapatinib, and the animals were sacri-
ficed after 2 weeks (Figure 5A). Treatment with trametinib alone
resulted in a significant decrease in tumor volume after 1 week, with
no significant decrease in ensuing weeks even after increasing the
dosage of trametinib to 1.0 mg/kg, once daily, after 2 weeks of treat-
ment (Figure 5A, arrow). Treatment with both lapatinib and trame-
tinib resulted in significantly greater tumor regression compared to
treatment with trametinib alone (60% decrease in volume after
2 weeks of treatment; Figure 5A). Increasing the dose of trametinib
to 1.0 mg/kg, once daily, after 2 weeks in the combination group,
did not enhance tumor regression. Removal of drug led to rapid tumor
outgrowth in both trametinib and the combination groups within
2 weeks.
Treatment of established 608 and 366 (KRAS mutant) tumors
yielded a different pattern of response to trametinib alone and lapa-
tinib plus trametinib therapy. The 608 and 366 tumors treated with
trametinib showed a slight inhibition of growth after 1 week of
treatment compared with lapatinib-treated mice, which had to be
sacrificed after 1 week (366 tumor) or 3 weeks (608 tumor) of treat-
ment due to excess tumor burden (Figure 5, B and C ). In contrast,
combined treatment with lapatinib and trametinib significantly inhib-
ited further tumor proliferation and tumor size remained relatively
constant over the 3- to 4-week treatment period (Figure 5, B and
C ). Removal of drug from the lapatinib/trametinib cohort resulted
in the rapid outgrowth of the tumors within 2 to 3 weeks. In summary,
the in vivo treatment studies clearly show that in the orthotopic
setting three individual patient-derived tumors were more effectively
inhibited in their growth following the combined administration of
lapatinib and trametinib.
To determine the extent of MEK inhibition by trametinib in vivo,
we treated mice bearing 250 to 500 mm3 tumors with lapatinib,
trametinib, or the combination therapy for 24 hours before sacrifice
and then harvested tumors for generation of tumor lysates and anal-
ysis by Western blot and pMAPK array. As shown in Figure 6, in vivo
Figure 7. Relative phosphorylation of 366 tumor (KRAS mut), 608 tumor (KRAS mut), and 738 tumor (KRAS wt) xenografts treated with
vehicle control, lapatinib (65 mg/kg, orally, twice daily), trametinib (3 mg/kg, orally, daily), or combination of trametinib and lapatinib. (A–C)
Histograms depicting relative pAkt1(S473), pAkt2(S474), pErk1(T202/Y204), p53(S46), and p70S6K(T421/S424) levels in treated 366 tumor
(A), 608 tumor (B), and 738 tumor (C) xenografts. Significance is denoted as ***P < .001, **P < .01, and *P < .05.
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treatment with lapatinib did not substantially diminish the phos-
phorylation of ERK1/2. In contrast, treatment with either trametinib
or the combination of trametinib and lapatinib greatly reduced ERK
phosphorylation in 608 and 366 tumors (Figure 6, A and B). Inter-
estingly, the reduction in phospho-ERK in 738 tumors was strikingly
enhanced with the combination of trametinib and lapatinib (Fig-
ure 6C ). Immunohistologic assessment of phospho-ERK paralleled
the results fromWestern blot analysis. In all three tumors, treatment with
trametinib or the combination of trametinib and lapatinib decreased
the levels of phospho-ERK staining (Figure W3).
To assess how treatment impacted intracellular signaling pathways
of three patient-derived tumors, we interrogated the phosphorylation
of AKT isoforms (AKT1, 2, and 3), ERK 1 and 2, and p70S6 kinase
using an array format. Interestingly, as shown in Figure 7, treatment of
mice bearing 366, 608, or 738 tumors with trametinib yielded an
increase in AKT2 phosphorylation and a significant inhibition of
phosphorylation of ERK1 and p70S6 kinase (Figure 7, A–C ; see also
Figure W4). Treatment with both trametinib and lapatinib blunted
the increase in AKT2 phosphorylation observed with trametinib treat-
ment and led to a further reduction in p70S6 kinase phosphorylation.
In each of the tumors, we observed a significant inhibition of pERK1
upon trametinib treatment. Phosho-p53 activity remained nearly con-
stant between treatment groups of each assessed tumor type and is pre-
sented here a protein loading control. These results support a model
in which trametinib treatment leads to increased activation of AKT2
that is blunted by combinatorial treatment with lapatinib. Both treat-
ments have effects on the phosphorylation of ERK1 and 70S6 kinase,
consistent with ERK and AKT2 being key regulators of signaling in
these tumors.
Discussion
In this study, we show that concomitant inhibition of the EGFR
family and MAPK pathways augments the inhibition of tumor pro-
liferation in patient-derived pancreatic cancers propagated orthotopi-
cally in immunocompromised mice compared to treatment with
either agent alone. Treatment of five patient-derived tumors, including
both KRAS wild-type and mutant tumors, with lapatinib and trame-
tinib resulted in enhanced inhibition of tumor growth and reduced
the number of metastatic lesions compared to treatment with the single
inhibitors. Importantly, treatment of larger advanced tumors with lapa-
tinib and trametinib was significantly more effective in reducing the size
of established tumors than treatment with lapatinib or trametinib
alone. These observations contrast with in vitro results from treatment
of cells cultured from patient-derived tumors or established pancreatic
cancer cell lines in which treatment with lapatinib and/or trametinib
resulted in the enhanced inhibition of cell proliferation in only three
of eight cell lines tested. Notably, acute treatment of established tumors
with trametinib resulted in an increase in AKT2 phosphorylation that
was blunted in mice treated with both trametinib and lapatinib, con-
sistent with the possibility that lapatinib in combination with trame-
tinib may inhibit signals from treatment-dependent activation of
EGF family receptors, thus augmenting the inhibition of pancreatic
cancer cell proliferation. The augmented inhibitory response of patient-
derived tumors to combined therapy in an orthotopic xenograft model
points to the importance of the EGF signaling pathway and its con-
tributions to tumor cell growth in the in vivo setting. These data
underscore the importance of assessing therapeutic combinations in
appropriate xenograft models.
Our studies use a representative subset of tumors taken from
a panel of 15 patient-derived pancreatic tumors, two thirds of
which were high-grade tumors with 60% occurring as primary adeno-
carcinomas of the pancreas and 40% being derived from metastatic
lesions. The tumors remained both genetically and pathologically stable
when propagated over several generations as orthotopic xenografts in
immunocompromised mice allowing preclinical testing of drug effi-
cacy. OncogenicKRASmutations were observed in 10 of the 15 tumors,
and all mutations were in codon 12, whereas wild-type KRAS alleles
were observed in tumors derived from both primary and metastatic
lesions. A large fraction (more than 70%) of tumors exhibitedmutations
in TP53 and SMAD4. Using phospho-RTK arrays, we observed a high
frequency of activation of EGFR family RTKs, particularly EGFR
(100%) and HER2 (47%). Interestingly, expression of activated
FGF-R1 and 3 was observed in a high proportion of patient-derived
tumors, although the significance of such activation to tumor pro-
liferation is unclear.
Because of the prevalence of mutant KRAS in pancreatic cancer,
signaling pathways mediated by oncogenic KRAS, particularly BRAF
and MEK1/2, have been prime targets for therapeutic interdiction
with small molecules [15,16,29,30]. The studies described herein
use trametinib (GSK1120212) that is a potent and selective allosteric
inhibitor of the MEK1 and MEK2 enzymes [20–22]. Consistent
with previous studies [20,21], treatment with trametinib induced
significant inhibition of proliferation (IC50 in the nM range), with
most cell lines exhibiting either cytostatic or cytotoxic responses to
treatment in a 5-day growth assay. In addition, trametinib effectively
blocked activation of ERK and induced cell cycle arrest in G1 as re-
ported previously [31].
In orthotopically xenografted patient-derived tumors, trametinib
(0.3 mg/kg) was effective in inhibiting tumor growth when admin-
istered 1week after tumor implantation in animals. Two patient-derived
tumors (450 and 232) were particularly sensitive to monotherapy with
trametinib with no net tumor growth observed at necropsy after
5 weeks. In experiments, wherein tumors were allowed to grow for
4 to 5 weeks to an advanced size before treatment, trametinib treatment
reduced the rate of tumor growthmore effectively in theKRASwild-type
738 tumor. In several experiments, increasing the dose of trametinib
from 0.3 to 1 mg/kg failed to evoke greater inhibition of tumor growth,
indicating that the dose of 0.3 mg/kg was sufficient for the observed
biologic response. Increasing dosage of trametinib to 3 mg/kg for more
that 1 week was toxic to the tumor-bearing mice (data not shown). Our
studies support the conclusion that trametinib as a single agent exhibits
high potency and is efficacious in inhibiting pancreatic cancer growth in
culture and in an in vivo orthotopic xenograft model. Recent clinical
studies have shown that trametinib exhibits clinical activity in mela-
noma and is tolerable with manageable side effects, thus paving the
way for additional studies in patients with mutant KRAS and BRAF
tumors [32,33].
The relative ubiquitous expression of EGFRs and the frequent
expression of HER2 have made these receptors targets for therapy
in pancreatic cancer [34,35]. In general, EGFR inhibitors have
yielded modest effectiveness in tumor inhibition studies in mouse
xenograft models [34–36]. In the experiments reported here, lapatinib
treatment failed to inhibit the growth of four of the five patient-derived
tumors examined. The 450 tumor, a low-grade primary adenocarci-
noma, which expressed both activated EGFR and HER2, showed a
statistically significant difference in growth with lapatinib treatment.
Our data are consistent with the observations that only a small percentage
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of pancreatic cancers will respond to lapatinib treatment alone, reflecting
the relative activation of the EGFR and HER2 pathways in concert
with the strong activation of signaling to MEK1/2 downstream of
mutant KRAS.
The role of HER2 signaling in pancreatic cancers is poorly under-
stood. In studies of patients undergoing curative resection of their
pancreatic cancer, patients with HER2 overexpression had signifi-
cantly shorter survival times than those with HER2 normal expression
[13]. In tumor xenograft models, combined treatment with cetuximab
(anti-EGFR monoclonal antibody) and trastuzumab (anti-HER2
monoclonal antibody) was shown to be superior to gemcitabine treat-
ment in three different pancreatic cell lines [14]. Interesting, dual treat-
ment with cetuximab and trastuzumab is reported to be associated with
the disruption of EGFR/HER2 dimerization [14], suggesting that
heterodimer signaling may contribute to pancreatic tumor growth.
Our observations that treatment with lapatinib and trametinib provides
significantly more effective inhibition of tumor growth (compared to
either agent alone) in two different experimental models indicates that
EGF and HER2 receptor signaling provides supportive growth signals
to tumors growing in the orthotopic environment of the pancreas.
Although limited to one patient-derived tumor, it is interesting that
the KRAS wild-type tumor (738) appeared to be particularly sensitive
to combined treatment, showing a more significant reduction in size
following combined treatment.
The mechanism by which lapatinib augments the inhibitory effects
of trametinib is unclear. One possibility is that orthotopically
implanted tumors respond to factors produced by the tumor micro-
environment. In support of this, we have observed that orthotopically
implanted 608 tumors have readily detectable levels of amphiregulin, a
well-studied ligand for EGF family receptors. Interestingly, cultured
608 cells express significantly lower levels of amphiregulin (D.M.W.,
J.M.L., and T.W.B., unpublished observations). Thus, in vivo, the pro-
liferative response of tumors may be driven in part by ligand-dependent
activation of MEK and ERK, perhaps through the normal allele of
KRAS or perhaps through other members of the RAS family (N- or
H-RAS). A second possibility is suggested by recent evidence that in
breast cancer cells inhibition of MEK1/2 leads to the feedback
activation/reprogramming of RTKs and increased AKT and MEK sig-
naling [24,25]. Consistent with this possibility, we observed that in vivo
treatment with trametinib leads to increased AKT2 phosphorylation
that was blunted by lapatinib treatment. Finally, we cannot rule out that
combination therapy targets signaling pathways separate to MEK and
AKT that are required for tumor cell proliferation. Additional experi-
ments will be required to explore these possible mechanisms in detail.
During the course of our studies, Diep et al. [37] reported that com-
bination treatments of erlotinib and two MEK inhibitors, RDEA119
and AZD6244, showed significant synergistic effect compared with the
corresponding single drug treatments in pancreatic cancer cell lines with
wild-type KRAS (BxPC-3 and Hs 700T) but not in cell lines with
mutant KRAS (MIA PaCa-2 and PANC-1). Diep et al. [37] also
reported that enhanced antitumor activity was observed with combi-
nation treatment in the BxPC-3 and MIA PaCa-2 mouse sub-
cutaneous xenograft models. Both the data presented herein and the
results of Diep et al. [37] indicate that while inhibition of the MAPK
pathways with trametinib or other MEK1/2 inhibitors is likely to be
effective in patients with pancreatic cancer, combined therapy may pro-
vide measurable enhancement in tumor response and a rationale for
consideration of this combination in clinical trials in patients with
pancreatic cancer.
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Figure W1. Dose-response curves for BxPC-3 (A), an established pancreatic cancer cell line, and 366 (B), a patient-derived cell line.
Circles represent trametinib (GSK1120212) alone, and squares are trametinib (GSK1120212) in combination with 1.0 μM lapatinib. Hori-
zontal dotted line indicates cell number initially plated. Vertical dotted lines indicate IC50 for each treatment.
Figure W2. (A) 366 Cells were serum starved for 4 hours and then
treated with either 1 μM lapatinib, 0.3 μM trametinib, or the com-
bination (+L+T) for 1 hour before being stimulated with 100 ng/ml
EGF for 30 minutes. pERK and Ran were quantitated and pERK
was divided by Ran to determine changes in phosphorylation.
Phosphorylated protein level was divided by total protein level to
yield quantitative values.
Figure W3. In vivo effect of lapatinib and trametinib on ERK1/2 phosphorylation measured by immunohistochemistry. Representative
micrographs (original magnification, ×40) from patient-derived orthotopic tumor xenografts [(A) 366 tumor and (B) 738 tumor] treated for
24 hours with vehicle control, lapatinib (65 mg/kg, twice daily), trametinib (3 mg/kg, daily), or combination therapy. Phospho-ERK1/2
most intensely stains the pancreatic ductal adenocarcinoma cells in the control and lapatinib-treated mice, while limited or no staining
is observed in trametinib- and combination-treated mice.
Figure W4. Relative phosphorylation of 366 tumor (KRAS mut), 608 tumor (KRAS mut), and 738 tumor (KRAS wt) xenografts treated with
vehicle control, lapatinib (65 mg/kg, orally, twice daily), trametinib (3 mg/kg, orally, daily), or combination of trametinib and lapatinib (T +
L). (A–C) Representative images of pMAPK arrays of whole tumor lysates from 366 tumor (A), 608 tumor (B), and 738 tumor (C) xeno-
grafts under the above treatment conditions. Relative pAkt1 (1), pAkt2 (2), pErk1 (3), pErk2 (4), p53 (5), and p70S6 kinase (6) levels
are highlighted.
